One of the nation's leading life science and technology developers has sold a piece of its expansive Bay Area portfolio as part of a broad shift away from traditional office assets and to higher-demand biotech uses.

One of the nation's leading life science and technology developers has sold a piece of its expansive Bay Area portfolio as part of a broad shift away from traditional office assets and to higher-demand biotech uses.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In